PAP
OLMA icon

Persistent Asset Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Persistent Asset Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,069
Closed -$202K – 436
2025
Q4 		$227K Buy
+9,069
New +$161K 0.1% 206
2025
Q3 		– Sell
-58,333
Closed -$350K – 281
2025
Q2 		$248K Buy
58,333
+35,345
+154% +$158K 0.18% 101
2025
Q1 		$86.4K Buy
+22,988
New +$116K 0.07% 117

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Persistent Asset Partners's OLMA Position: Q1 2026 in Review

Persistent Asset Partners sold out of Olema Pharmaceuticals (OLMA) in Q1 2026, closing a stake of 9,069 shares — an estimated $202K sold.

Persistent Asset Partners first reported a position in OLMA in Q1 2025 and held it in 3 quarters. The position peaked at $248K in Q2 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Persistent Asset Partners reported no remaining Olema Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 9,069 Olema Pharmaceuticals shares in Q1 2026, an estimated $202K.
  • Persistent Asset Partners first reported a position in Olema Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Persistent Asset Partners's Olema Pharmaceuticals position peaked at $248K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.